Prevention of Alzheimer's disease in high risk groups: statin therapy in subjects with PSEN1 mutations or heterozygosity for apolipoprotein E epsilon 4

Affiliations

Daniel A Pollen et al. Alzheimers Res Ther. 2010.

. 2010 Oct 29;2(5):31.

doi: 10.1186/alzrt55.

¹ Department of Neurology, University of Massachusetts Medical School, Worcester, MA 01655, USA. pollend@ummhc.org.

No abstract available

Cited by

Statins, cognition, and dementia—systematic review and methodological commentary.
Power MC, Weuve J, Sharrett AR, Blacker D, Gottesman RF. Power MC, et al. Nat Rev Neurol. 2015 Apr;11(4):220-9. doi: 10.1038/nrneurol.2015.35. Epub 2015 Mar 24. Nat Rev Neurol. 2015. PMID: 25799928 Free PMC article.
Extracting β-amyloid from Alzheimer's disease.
Dries DR, Yu G, Herz J. Dries DR, et al. Proc Natl Acad Sci U S A. 2012 Feb 28;109(9):3199-200. doi: 10.1073/pnas.1121560109. Epub 2012 Feb 10. Proc Natl Acad Sci U S A. 2012. PMID: 22328154 Free PMC article. No abstract available.
Effects of Plasma Lipids and Statins on Cognitive Function.
Li R, Wang TJ, Lyu PY, Liu Y, Chen WH, Fan MY, Xu J. Li R, et al. Chin Med J (Engl). 2018 Feb 20;131(4):471-476. doi: 10.4103/0366-6999.225062. Chin Med J (Engl). 2018. PMID: 29451153 Free PMC article. Review.
HDL-like-Mediated Cell Cholesterol Trafficking in the Central Nervous System and Alzheimer's Disease Pathogenesis.
Borràs C, Mercer A, Sirisi S, Alcolea D, Escolà-Gil JC, Blanco-Vaca F, Tondo M. Borràs C, et al. Int J Mol Sci. 2022 Aug 19;23(16):9356. doi: 10.3390/ijms23169356. Int J Mol Sci. 2022. PMID: 36012637 Free PMC article. Review.
Cholesterol and Dementia: A Long and Complicated Relationship.
McFarlane O, Kędziora-Kornatowska K. McFarlane O, et al. Curr Aging Sci. 2020;13(1):42-51. doi: 10.2174/1874609812666190917155400. Curr Aging Sci. 2020. PMID: 31530269 Free PMC article. Review.

1. Sherrington R, Rogaev El, Liang Y, Rogaeva EA, Levesque G, Ikeda M, Chi H, Lin C, Li G, Holman K. et al.Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. Nature. 1995;375:754–760. doi: 10.1038/375754a0. - DOI - PubMed
1. Selkoe DJ. A beta oligomers - a decade of discovery. J Neurochem. 2007;101:1172–1184. doi: 10.1111/j.1471-4159.2006.04426.x. - DOI - PubMed
1. Li S, Shankar GM, Selkoe DJ. How do soluble oligomers of amyloid beta-protein impair hippocampal synaptic plasticity? Front Cell Neurosci. 2010;4:5. - PMC - PubMed
1. Moonis M, Swearer JM, Dayaw MP, St George-Hyslop P, Rogaeva E, Kawarai T, Pollen DA. Familial Alzheimer disease: decreases in CSF Abeta42 levels precede cognitive decline. Neurology. 2005;65:323–325. doi: 10.1212/01.wnl.0000171397.32851.bc. - DOI - PubMed
1. Petrie EC, Cross DJ, Galasko D, Schellenberg GD, Raskind MA, Peskind ER, Minoshima S. Preclinical evidence of Alzheimer changes: convergent cerebrospinal fluid biomarker and fluorodeoxyglucose positron emission tomography findings. Arch Neurol. 2009;66:632–637. doi: 10.1001/archneurol.2009.59. - DOI - PMC - PubMed